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Mutations that restrict replication of dengue virus have been sought for the generation of recombinant live-attenuated
dengue virus vaccines. Dengue virus type 4 (DEN4) was previously grown in Vero cells in the presence of 5-fluorouracil, and
the characterization of 1248 mutagenized, Vero cell passaged clones identified 20 temperature-sensitive (ts) mutant viruses
that were attenuated (att) in suckling mouse brain (J. E. Blaney, Jr., D. H. Johnson, C. Y. Firestone, C. T. Hanson, B. R. Murphy,
and S. S. Whitehead, 2001, J. Virol. 75(20), 9731–9740). The present investigation has extended these studies by identifying
an additional 22 DEN4 mutant viruses which have a small plaque size (sp) phenotype in Vero cells and/or the liver cell line,
HuH-7. Five mutant viruses have a sp phenotype in both Vero and HuH-7 cells, three of which are also ts. Seventeen mutant
viruses have a sp phenotype in only HuH-7 cells, 13 of which are also ts. Each of the sp viruses was growth restricted in the
suckling mouse brain, exhibiting a wide range of reduction in replication (9- to 100,000-fold). Complete nucleotide sequence
was determined for the 22 DEN4 sp mutant viruses, and nucleotide substitutions were found in the 3-untranslated region
(UTR) as well as in all coding regions except NS4A. Identical mutations have been identified in multiple virus clones,
suggesting that they may be involved in the adaptation of DEN4 virus to efficient growth in Vero cells. Six of the 22 sp 5-FU
mutant viruses lacked coding mutations in the structural genes, and 17 recombinant DEN4 viruses were generated which
separately encoded each of the mutations observed in these six sp viruses. Analysis of the recombinant DEN4 viruses
defined the genetic basis of the sp, ts, and att phenotypes observed in the six sp viruses. Mutations in NS1, NS3, and the
3-UTR were found to confer a greater than 100-fold, 10,000-fold, and 1000-fold reduction in replication of rDEN4 virus inINTRODUCTION
The dengue (DEN) viruses (serotypes 1 to 4), members
of the Flavivirus genus, contain a single-stranded posi-
tive-sense RNA genome of approximately 10,600 nucle-
otides (nt) (Monath and Heinz, 1996). The genome orga-
nization of DEN viruses is 5-UTR-C-prM-E-NS1-NS2A-
NS2B-NS3-NS4A-NS4B-NS5-UTR-3 (UTR, untranslated
region; C, capsid; prM, membrane precursor; E, enve-
lope; NS, nonstructural) (Chang, 1997; Rice, 1996). A
single viral polypeptide is cotranslationally processed by
viral and cellular proteases generating three structural
proteins (C, M, and E) and seven NS proteins.
The DEN viruses are transmitted to humans by Aedes
mosquitoes, which inhabit most of the tropical and semi-
tropical regions of the world. DEN viruses cause more
disease and death of humans than any other arbovirus,
and more than 2.5 billion people live in regions with
1 To whom correspondence and reprint requests should be ad-
dressed at NIH, NIAID, LID, Bldg. 50, Room 6515, 50 South Drive, MSC125endemic dengue infection (Gubler, 1998). Annually, there
are an estimated 50–100 million cases of dengue fever
(DF) and 500,000 cases of the more severe and poten-
tially lethal dengue hemorrhagic fever/dengue shock
syndrome (DHF/DSS) (Gubler and Meltzer, 1999). Den-
gue fever is an acute infection characterized by fever,
retro-orbital headache, myalgia, and rash. At the time of
defervescence during DF, a more severe complication of
DEN virus infection, DHF/DSS, may occur, which is char-
acterized by a second febrile period, hemorrhagic man-
ifestations, hepatomegaly, thrombocytopenia, and
hemoconcentration, which may lead to potentially life-
threatening shock (Gubler, 1998).
The sites of DEN virus replication in humans and their
importance and relationship to the pathogenesis of DF
and DHF/DSS are still incompletely understood (Innis,
1995). In addition to replication in lymphoid cells, it has
become evident that the liver is involved in DEN infection
of humans. Transient elevations in serum alanine ami-
notransferase (ALT) and aspartate aminotransferase
(AST) levels are observed in the majority of DEN virus-SCID mice transplanted with HuH-7 cells, respectively, wh
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infected patients and hepatomegaly is observed in some
patients (Kalayanarooj et al., 1997; Kuo et al., 1992; Mo-ich ser
laque;0042-6822/02
han et al., 2000; Wahid et al., 2000). DEN virus antigen-
positive hepatocytes are seen surrounding areas of ne-
crosis in the liver of fatal cases (Couvelard et al., 1999;
Huerre et al., 2001), from which dengue virus sequences
were identified using RT-PCR (Rosen et al., 1999). Of
potential importance to the etiology of severe dengue
virus infection, three studies have demonstrated that the
mean levels of serum ALT and AST were significantly
increased in patients with DHF/DSS than those with DF
(Kalayanarooj et al., 1997; Mohan et al., 2000; Wahid et
al., 2000). As expected, elevation of serum liver enzymes
has previously been observed in clinical trials of DEN
virus vaccine candidates (Durbin et al., 2001; Eckels et
al., 1984; Edelman et al., 1994; Kanesa-thasan et al., 2001;
Vaughn et al., 1996).
Based on the increasing disease burden associated
with DEN virus infection over the past several decades,
a vaccine that confers protection against the four dengue
virus serotypes is needed, but none is presently li-
censed. Because of the increased risk for severe DHF/
DSS associated with secondary infection with a heterol-
ogous DEN virus serotype (Burke et al., 1988; Halstead et
al., 1977; Thein et al., 1997), an effective vaccine must
confer simultaneous protection against each of the four
DEN virus serotypes. Several approaches are presently
being pursued to develop a tetravalent vaccine against
the dengue viruses (Bancroft et al., 1984; Bhamarapravati
and Sutee, 2000; Butrapet et al., 2000; Guirakhoo et al.,
2000, 2001; Huang et al., 2000; Kanesa-thasan et al.,
2001). One such approach, a live-attenuated DEN4 vac-
cine candidate, termed 2A30, was both attenuated and
immunogenic in a cohort of 20 volunteers (Durbin et al.,
2001). The recombinant 2A30 virus contains a 30-nt
deletion in the 3UTR which removes nucleotides
10,478–10,507 and was found to produce a low or unde-
tectable level of viremia in vaccinees at a dose of 105
PFU/vaccinee. An asymptomatic rash was reported in
50% of volunteers, and the only laboratory abnormality
observed was an asymptomatic, transient rise in the
serum ALT level in 5 of the 20 vaccinees. All 2A30
vaccinees developed serum-neutralizing antibodies
against DEN4 virus (mean titer: 1:580), and 2A30 was
not transmitted to mosquitoes that fed experimentally on
vaccinees (Troyer et al., 2001). Because of the desirable
properties conferred by the 30 mutation, chimeric vac-
cine candidates are being constructed which contain the
structural genes of DEN virus type 1, 2, and 3, in the
attenuated DEN4 background bearing the genetically
stable 30 mutation. Attenuating mutations outside of
the structural genes are particularly attractive for inclu-
sion in antigenic chimeric vaccine candidates because
they will not affect the infectivity or immunogenicity con-
ferred by the major mediator of humoral immunity to DEN
viruses, the envelope protein.
The presence of rash and elevated ALT levels sug-
gests that the 2A30 vaccine candidate may be
slightly underattenuated in humans. Similarly, many
previous attempts to develop live-attenuated dengue
virus vaccines have yielded vaccine candidates that
were either over- or underattenuated in humans, some
of which also induced elevation of serum ALT and AST
levels (Bhamarapravati and Yoksan, 1997; Eckels et al.,
1984; Innis et al., 1988; Kanesa-thasan et al., 2001;
McKee et al., 1987). Therefore, we are developing a
menu of point mutations conferring temperature-sen-
sitive (ts), small-plaque (sp), and attenuation (att) phe-
notypes capable of attenuating DEN4 viruses to a
varying degree (Blaney et al., 2001; Hanley et al.,
2002). We have previously described 20 mutant vi-
ruses that exhibit a ts, but not sp, phenotype in Vero
cells or HuH-7 liver cells and that show attenuated
replication in mouse brain. Addition of such mutations
to 2A30 or to other novel DEN vaccine candidates
should yield vaccine candidates that exhibit a more
satisfactory balance between attenuation and immu-
nogenicity.
In the present study, we have extended our analysis of
the panel of 1248 DEN4 virus clones previously gener-
ated by mutagenesis with 5-fluorouracil (5-FU) (Blaney et
al., 2001), by identifying a set of 22 sp mutant viruses,
some of which also have a ts phenotype. Small plaque
mutant viruses were sought since such viruses are often
attenuated in humans (Bhamarapravati and Yoksan,
1997; Butrapet et al., 2000; Crowe et al., 1994a,b; Eckels
et al., 1980; Innis et al., 1988; Murphy and Chanock, 2001;
Takemoto, 1966). Because natural infection with dengue
viruses and vaccination with 2A30 may be associated
with liver toxicity in humans, we identified mutant viruses
with restricted replication in human liver cells. Accord-
ingly, viruses were screened for plaque size and temper-
ature sensitivity in the human hepatoma cell line, HuH-7,
as well as in Vero cells. Here we describe the in vitro ts
phenotype, nucleotide sequence, and growth properties
in suckling mice of 22 sp DEN4 mutant virus clones. Six
sp 5-FU mutant viruses were found to contain coding
mutations in only the NS genes and/or nucleotide sub-
stitutions in the 3-UTR, which would facilitate the gen-
eration of antigenic chimeric viruses. The genetic basis
of the observed sp, ts, and att phenotypes was identified
for these six viruses using reverse genetics to generate
recombinant DEN4 (rDEN4) viruses containing individual
mutations identified in the panel of sp DEN4 mutant
viruses. Finally, these six 5-FU mutant DEN4 viruses and
corresponding rDEN4 mutant viruses were evaluated for
replication in a novel small animal model for DEN4 virus
replication, SCID mice transplanted with HuH-7 cells
(SCID-HuH-7). These studies begin to address the utility
of examining DEN virus infection in SCID mouse-xe-
nograft models for vaccine development (An et al., 1999;
Lin et al., 1998).
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RESULTS
Identification of DEN4 5-fluorouracil mutant viruses
with a sp phenotype
The generation of a panel of 1248 virus clones from a
wild-type DEN4 2A virus suspension mutagenized by
5-FU has been described previously (Blaney et al., 2001).
In the present study 22 mutant viruses with a sp pheno-
type were identified. The plaque size of representative
mutant viruses is illustrated in Fig. 1. The plaque size of
DEN4 2A-13 virus (a parallel-passaged virus with a wild-
type phenotype derived from control cultures not treated
with 5-FU) was consistently smaller in HuH-7 cells than
that observed in Vero cells (Fig. 1A). Mutant viruses 569
and 1189 (Fig. 1B) were sp in both Vero and HuH-7 cells.
In contrast, 5-FU mutant virus clones 311 and 1083 (Fig.
1C) were sp in only HuH-7 cells, suggesting a liver
cell-specific defect in replication within this phenotypic
group. As indicated in Table 1, five mutant viruses were
found to have a sp phenotype in both Vero and HuH-7
cells, while 17 viruses had a sp phenotype in only HuH-7
cells. Each 5-FU mutant virus clone was compared for a
sp or ts phenotype with three control viruses, 2A-13,
wild-type rDEN4, and rDEN430. The recombinant vi-
ruses, rDEN4 and rDEN430, each had a plaque size in
Vero and HuH-7 cells similar to that of DEN4 2A-13,
indicating that the 30 mutation does not confer a sp
phenotype (Table 1).
Most of the sp 5-FU mutant viruses also had a ts
phenotype in Vero and/or HuH-7 cells (Table 1) since
mutant viruses were initially screened for temperature
sensitivity (see Materials and Methods). Temperature
sensitivity was defined as a 2.5 or 3.5 log10PFU/ml re-
duction in virus titer in Vero or HuH-7 cells, respectively,
at restrictive temperature compared to the permissive
temperature of 35°C as previously defined (Blaney et al.,
2001). Three mutant viruses (574, 1269, and 1189) were
sp and ts in both Vero and HuH-7 cells, while nine mutant
viruses (506–326 in Table 1) were found to be ts in both
cell types but sp only in HuH-7 cells. Four viruses (1104,
952, 738, and 1083) were found to have a wild-type
phenotype in Vero cells but were both sp and ts in HuH-7
cells. These four mutant viruses each had a 6000- to
600,000-fold reduction in virus titer at 39°C in HuH-7
cells with only a 6- to 40-fold reduction at 39°C in Vero
cells. Finally, sp mutant viruses were identified which did
not have a ts phenotype in either cell line; two of these
viruses (569 and 761) were sp in both Vero and HuH-7
cells and four viruses (1096–1012) were sp in only HuH-7
cells (Table 1). These six viruses with only sp phenotypes
were most likely found in the initial temperature sensi-
tivity screen in a 96-well plate format because of their
restricted growth properties at 39°C, which did not per-
mit detection by immunostaining. As described previ-
ously, the 30 mutation did not confer temperature sen-
sitivity in either cell line (Blaney et al., 2001).
The sp 5-FU mutant viruses have restricted
replication in suckling mouse brain
The 22 sp DEN4 5-FU mutant viruses were evaluated
for their ability to replicate in the brain of one-week-old
suckling mice. As a marker for in vivo attenuation, their
level of replication was compared with that of the paral-
FIG. 1. Small-plaque phenotype of 5-FU mutant DEN4 viruses in Vero or HuH-7 cells. Serial 10-fold dilutions of wild-type DEN4 2A-13 (A), 5-FU
mutant viruses 569 and 1189 (B), and 5-FU mutant viruses 1083 and 311 (C) were inoculated onto confluent Vero and HuH-7 cell monolayers in 24-well
plates. Following incubation at 35°C for 5 days, plaques were visualized by immunoperoxidase staining. Viruses with a plaque size that was 1 mm
in Vero cells or 0.4 mm in HuH-7 cells (approximately 50% the size of wild-type DEN4 2A-13) were designated as having the small-plaque (sp)
phenotype. Mutant viruses 569 and 1189 (B) were sp in both Vero and HuH-7 cells, and 311 and 1083 (C) were sp in only HuH-7 cells.
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lel-passaged control virus with a wild-type phenotype,
2A-13 (Table 1). Nineteen of 22 sp mutant viruses had a
greater than 100-fold reduction in virus replication in the
brain of suckling mice compared to 2A-13 and nine
viruses had a reduction of greater than 10,000-fold.
The five mutant viruses which were sp in both Vero
and HuH-7 cells were 5000- to 100,000-fold restricted in
replication compared to 2A-13. Two of these mutant vi-
ruses, 569 and 761, were not ts in either cell line but had
a reduction in virus titer of greater than 10,000-fold in
mouse brain, suggesting that the sp phenotype in both
Vero and HuH-7 cells may be an important surrogate
marker for attenuated replication in suckling mouse
brain. 5-FU mutant viruses which were sp in only HuH-7
cells had a more variable range of replication in mouse
brain. Three viruses had a mean reduction in virus titer of
less than 10-fold when compared to 2A-13 virus. How-
ever, 8 of 13 viruses which were ts in Vero and/or HuH-7
cells but sp in only HuH-7 cells had a greater than
5000-fold reduction in virus replication. The results of the
in vivo replication analysis of the previously described 20
ts 5-FU mutant viruses (Blaney et al., 2001) and the 22 sp
mutant viruses are summarized in Table 2. Mutant vi-
ruses with both a sp and ts phenotype were found to
have a significantly greater level of attenuation in the
brain of suckling mice when compared to viruses with
only a ts phenotype.
Sequence analysis of the sp 5-FU mutant viruses
To initiate an analysis of the genetic basis of the ts, sp,
or att phenotype of the 22 sp mutant viruses, the com-
TABLE 1
Temperature-Sensitive (ts) and Mouse Brain Attenuation (att) Phenotypes of 5-FU DEN4 Mutant Viruses
Which Also Exhibit a Small Plaque (sp) Phenotype
Phenotype
Virus
Mean virus titer (log10PFU/ml) at indicated temp. (°C)
Replication in suckling miceb
sp ts Vero cells HuH-7 cells
Vero HuH-7 Vero HuH-7 35 37 38 39 a 35 37 38 39  n
Mean virus
titer  SE
(log10PFU/g
brain)
Mean log10
reduction
from wtc
— — — — 2A-13 7.9 7.5 7.7 7.2 0.7 7.9 7.7 7.3 6.9 1.0 66 6.6 0.1d —
— — — — rDEN4 7.9 7.6 7.7 7.3 0.6 8.1 7.6 7.5 6.7 1.4 66 6.1 0.1d —
— — — — rDEN430 7.3 6.6 6.6 6.1 1.2 7.3 7.2 6.9 5.9 1.4 64 5.6 0.1d 0.5
    574 6.6 f 5.5 3.8 1.6e 5.0 6.6 f 4.9 5.0 1.6 5.0 6 2.1 0.1 5.1
    1269 5.3 f 4.8 3.9 1.6 3.7 4.0 f 2.4 2.0 1.6 2.4 6 2.7 0.2 4.1
    1189 6.3 f 5.2 4.5 3.8 2.5 5.5 f 3.7 2.3 1.6 3.9 12 3.2 0.4 3.7
  — — 569 5.8 f 5.6 5.6 3.7 2.1 6.2 f 6.0 5.7 5.0 1.2 12 1.9 0.1 4.6
  — — 761 5.0 f 4.7 4.2 2.7 2.3 5.6 f 5.3 4.5 2.6 3.0 12 2.0 0.1 4.2
—    506 7.0 6.8 5.6 2.6 4.4 6.7 f 4.3 1.6 2.0 4.7 6 2.2 0.1 4.7
—    1136 5.1 4.2 2.6 1.6 3.5 5.7 f 3.0 3.0 1.6 4.1 6 2.9 0.3 4.5
—    1029 6.9 5.8 5.8 2.9 4.0 7.0 f 5.8 5.2 2.5 4.5 6 2.2 0.1 4.2
—    1081 6.9 5.8 4.7 3.9 3.0 5.8 f 4.1 3.3 1.9 3.9 12 2.6 0.2 3.9
—    529 6.9 6.5 5.9 4.0 2.9 7.1 f 5.3 4.4 1.6 5.5 6 3.1 0.7 3.8
—    1114 6.7 6.4 6.2 2.5 4.2 5.7 f 3.0 2.9 1.9 3.8 6 2.7 0.3 3.7
—    922 7.3 7.2 6.8 3.8 3.5 7.4 f 5.3 4.1 3.0 4.4 12 3.5 0.1 2.9
—    311 6.9 5.9 4.3 1.5 5.4 7.1 f 5.4 3.6 1.6 5.5 12 6.1 0.3 0.9
—    326 6.6 5.7 4.5 3.1 3.5 7.0 f 5.5 4.1 2.0 5.0 6 6.0 0.1 0.9
—  —  1104 7.1 6.8 6.8 6.1 1.0 7.2 f 6.4 5.8 2.8 4.4 6 2.2 0.1 4.7
—  —  952 7.1 7.0 6.7 5.6 1.5 7.3 f 6.3 5.6 3.0 4.3 6 2.4 0.3 4.5
—  —  738 6.5 6.0 5.9 5.7 0.8 6.9 f 6.1 5.0 3.1 3.8 12 4.4 0.4 2.3
—  —  1083 7.4 7.3 7.4 5.8 1.6 7.4 f 6.6 4.5 1.6 5.8 12 4.5 0.4 2.0
—  — — 1096 7.5 7.1 6.9 5.5 2.0 7.5 f 6.6 5.6 4.8 2.7 6 2.9 0.2 3.5
—  — — 1021 7.0 6.9 6.6 6.3 0.7 6.9 f 5.7 4.4 4.0 2.9 6 3.9 0.6 2.6
—  — — 1023 6.6 6.4 6.0 5.8 0.8 6.1 f 5.6 4.7 3.3 2.8 12 4.2 0.3 2.3
—  — — 1012 7.5 7.1 7.0 5.7 1.8 7.4 f 6.8 6.8 5.6 1.8 6 6.1 0.1 0.8
a Reduction in mean virus titer (log10PFU/ml) at 39°C compared to permissive temperature (35°C).
b Groups of six suckling mice were inoculated i.c. with 104 PFU virus. Brains were removed 5 days later, homogenized, and titered in Vero cells.
c Determined by comparing mean viral titers of mice inoculated with mutant virus and concurrent 2A-13 wild type (wt) virus control (n  6 or 12).
d Average of 11 experiments with a total of 64 to 66 mice per group.
e Underlined values indicate a 2.5 or 3.5 log10PFU/ml reduction in titer in Vero cells or HuH-7 cells, respectively, at indicated temperature when
compared to permissive temperature (35°C).
f Small plaque size at 35°C; small plaques have a diameter of 1.0 mm compared to wild-type plaque diameter of 1.5–2.0 mm in Vero cells, or a
diameter of 0.4 mm compared to wild-type plaque diameter of 0.75 to 1.0 mm in HuH-7 cells.
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plete nucleotide sequence of each virus genome was
determined and is summarized in Table 3 (sp in Vero and
HuH-7 cells) and Table 4 (sp in only HuH-7 cells). All
identified mutations were nucleotide substitutions, as
deletions or insertions were not observed. Point muta-
tions were distributed throughout the genome, including
the 3-UTR as well as in all coding regions. Because all
5-FU mutant viruses were found to have at least two
mutations (two to six), the observed phenotypes cannot
be directly attributed to a specific mutation. The majority
of sp viruses also contained translationally silent point
mutations (none to four) in the structural or nonstructural
coding regions. However, these silent mutations are not
expected to contribute to the observed phenotypes. Six
of the 22 sp mutant viruses (Tables 3 and 4) were found
to have mutations in only the NS genes and/or the
3-UTR, indicating that the sp phenotype can be con-
ferred by mutations outside of the structural genes.
Presence of identical mutations in multiple 5-FU
mutant viruses
Analysis of the complete nucleotide sequence data for
the 5-FU mutant viruses identified several repeated mu-
tations which were present in two or more viruses. Such
mutations were also identified previously during our
analysis of twenty 5-FU mutant viruses with a ts but not
sp phenotype (Blaney et al., 2001). Because these muta-
tions occurred in viruses together with additional muta-
tions, the contribution of the repeated mutations to the
observed sp, ts, and att phenotypes remains unclear.
Table 5 lists the repeated mutations found among the 20
TABLE 2
Viruses with both ts and sp Phenotypes are More Restricted in
Replication in Mouse Brain Than Those with Only a ts Phenotype
Cell culture
phenotype
Number
of viruses
Mean log10 reduction in virus
titer from controla,b
tsc 20 2.1 0.2
sp 6 3.0 0.6
ts/sp 16 3.5 0.3
a Determined by comparing mean viral titers of groups of mice
inoculated with mutant virus and concurrent 2A-13 parallel-passaged
control virus.
b Significant difference between ts group and ts/sp group, Tukey–
Kramer test (P  0.05).
c 20 ts mutant viruses without an sp phenotype were previously
described (Blaney et al., 2001).
TABLE 3
Nucleotide and Amino Acid Differences of the 5-FU Mutant DEN4 Viruses Which Produce Small Plaques in Both Vero and HuH-7 Cells
Virus
Mutations in UTR or in coding regions that result in an amino acid substitution
Mutations in coding regions that do not result
in an amino acid substitution
Nucleotide position Gene/region Nucleotide change Amino acid changea Nucleotide position Gene Nucleotide change
569 826 prM G  A R242K 1946 E C  U
832 prM C  U P244L
7546 NS4B C  U A2482V
10,275 3 UTR A  U n/a
10,279 3 UTR A  U n/a
574 1455 E G  U V452F 1349 E C  U
1963 E U  C V621A
3880 NS2A A  G K1260R
7546 NS4B C  U A2482V
7615 NS5 A  G N2505S
10,413 3 UTR A  G n/a
761 424 C U  C I108T None
2280 E U  C F727L
7131 NS4B A  G T2344A
7486 NS4B A  G N2462S
1189b 3303 NS1 A  G R1068G 6719 NS4A U  C
4812 NS3 G  A V1571I
5097 NS3 G  A D1666N
7182 NS4B G  A G2361S
1269 2112 E U  C F671L 542 prM C  U
3256 NS1 G  A G1052E
3993 NS2A U  C F1298L
7183 NS4B G  U G2361V
a Amino acid position in DEN4 polyprotein beginning with the methionine residue of the C protein (nt 102–104). Wild-type amino acid on left of amino
acid position; mutant amino acid on right.
b Virus contains missense mutations in only the nonstructural genes.
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TABLE 4
Nucleotide and Amino Acid Differences of the 5-FU Mutant DEN4 Viruses Which Produce Small Plaques in Only HuH-7 Cells
Virus
Mutations in UTR or in coding regions that
result in an amino acid substitution
Mutations in coding regions that do not
result in an amino acid substitution
Nucleotide
position Gene/region
Nucleotide
change
Amino acid
changea
Nucleotide
position Gene
Nucleotide
change
311 1519 E A  G N473S 6761 NS4A C  U
2305 E G  A R735K 10,070 NS5 U  C
4896 NS3 G  U A1599S
326 1587 E C  U P496S 1523 E G  A
7546 NS4B C  U A2482V 6080 NS3 U  C
10,070 NS5 U  C
506 1455 E G  U V452F 3887 NS2A A  G
1902 E G  A V601M 5789 NS3 G  C
7546 NS4B C  U A2482V
10,275 3 UTR A  U n/a
529 777 prM U  C S226P None
4641 NS3 A  G I1514V
7153 NS4B U  C V2351A
8245 NS5 U  C I2715T
10,279 3 UTR A  C n/a
738b 3540 NS2A G  A E1147K None
7162 NS4B U  C L2354S
922b 4306 NS2B A  G N1402S 7736 NS5 G  A
5872 NS3 C  U T1924I
7163 NS4B A  U L2354F
10,279 3 UTR A  C n/a
952 1449 E G  U V450L None
1455 E G  U V452F
7546 NS4B C  U A2482V
7957 NS5 U  C V2619A
9543 NS5 A  G I3148V
1012 1542 E A  G K481E 953 E A  G
7162 NS4B U  C L2354S 1205 E G  A
10,542 3 UTR A  G n/a 4425 NS2B U  C
1021 2314 E U  C I738T 665 prM C  A
3205 NS1 C  U A1035V 5750 NS3 C  U
4029 NS2A U  C C1310R 9959 NS5 C  U
7163 NS4B A  C L2354F
10,275 3 UTR A  U n/a
10,279 3 UTR A  U n/a
1023 2283 E G  A G728R 1001 E C  U
7182 NS4B G  A G2361S 1958 E A  G
3873 NS2A U  C
8486 NS5 C  U
1029 850 prM C  U A250V 3867 NS2A C  U
3087 NS1 A  G T996A
4891 NS3 U  C I1597T
1081b 2650 NS1 A  G N850S 6326 NS3 C  U
7163 NS4B A  U L2354F 9146 NS5 C  U
1083b 3702 NS2A G  A A1201T 3353 NS1 A  G
7153 NS4B U  C V2351A 6155 NS3 G  A
10,634 3 UTR U  C n/a
1096 892 prM G  A R264Q 665 prM C  A
7163 NS4B A  C L2354F 4427 NS2B G  A
8659 NS5 C  U P2853L
1104 1692 E G  A V531M None
5779 NS3 C  U A1893V
7546 NS4B C  U A2482V
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ts (not sp) mutant viruses described previously (Blaney et
al., 2001) and the 22 sp mutant viruses described here.
Repeated mutations were identified in the following
genes: two in E, two in NS3, five in NS4B, one in NS5,
and two in the 3-UTR. Interestingly, within a 30 nucleo-
tide region of NS4B (nt 7153–7182), there were five dif-
ferent nucleotide substitutions which were found in 16
viruses. Also at nt 7546 in NS4B, an amino acid substi-
tution (Ala 3 Val) was found in 10 different 5-FU mutant
viruses. The significance of these repeated mutations in
NS4B as well as in other DEN4 genomic regions remains
unclear, but a reasonable explanation for this phenom-
enon is that these mutations are involved in adaptation of
DEN4 virus for efficient growth in Vero cells. Alternatively,
these repeated mutations could represent loci of genetic
instability which have no correlation with adaptation to
growth in Vero cells.
Genetic basis of ts, sp, and att phenotypes in
suckling mice for selected 5-FU mutant viruses
As described above, six 5-FU mutant viruses (Tables 3
and 4) were found to have coding mutations in only the
NS genes and/or nucleotide substitutions in the 3-UTR:
5-FU mutant 738, 922, 1081, 1083, 1136, and 1189. Be-
cause of our particular interest in attmutations outside of
the structural gene region, we sought to identify the
individual mutations among these viruses which confer
the observed phenotypes. Seventeen mutations identi-
fied by sequence analysis resulted in a coding change or
a nucleotide change in the UTR and each was engi-
neered into an individual DEN4 cDNA clone. Virus was
successfully recovered and propagated containing each
defined mutation and tested for efficiency of plaque for-
mation in Vero and HuH-7 cells at various temperatures,
plaque-size phenotype, and growth properties in suck-
ling mice as was performed for the parental 5-FU mutant
viruses.
Table 6 lists the phenotypes of the six 5-FU mutant
parent viruses followed by those of the 17 rDEN4 viruses
encoding single mutations present in the parent virus.
For example, 5-FU mutant 1189 (parent), which was ts
and sp in both cell lines and had an almost 10,000-fold
reduction in replication in suckling mouse brain, con-
tained four coding mutations at nt position 3303 in NS1,
4812 and 5097 in NS3, and 7182 in NS4B. Analysis of the
four rDEN4 viruses containing each of these mutations
indicated that rDEN4-5097 had a ts, sp, and att pheno-
type, while rDEN4-3303, rDEN4-4812, and rDEN4-7182
had no discernible phenotypes, indicating that the mu-
tation at nt 5097 was responsible for the phenotype
TABLE 4—Continued
Virus
Mutations in UTR or in coding regions that
result in an amino acid substitution
Mutations in coding regions that do not
result in an amino acid substitution
Nucleotide
position Gene/region
Nucleotide
change
Amino acid
changea
Nucleotide
position Gene
Nucleotide
change
1114 709 prM A  G K203R 1076 E U  C
3693 NS2A A  G I1198V 1182 E C  U
4614 NS3 U  C F1505L 5690 NS3 C  U
7546 NS4B C  U A2482V
9942 NS5 A  G T3281A
1136b 3771 NS2A A  G R1224G 5621 NS3 A  G
4891 NS3 U  C I1597T
10,275 3 UTR A  U n/a
a Amino acid position in DEN4 polyprotein beginning with the methionine residue of the C protein (nt 102–104). Wild-type amino acid on left of amino
acid position; mutant amino acid on right.
b Viruses that contain missense mutations in only the nonstructural genes and/or mutations in the UTRs.
TABLE 5
Putative Vero Cell Adaptation Mutations Derived
from the Set of 5-FU Mutant Viruses
Nucleotide
position
Gene/region
(a.a. #)a
5-FU mutant viruses
Nucleotide
change
Amino acid
change
No. of viruses
with the
mutation
1455 E (452) G  U Val  Phe 5
2280 E (727) U  C Phe  Leu 2
4891 NS3 (1597) U  C Ile  Thr 2
4995 NS3 (1599) U  C Ser  Pro 8
7153 NS4B (2351) U  C Val  Ala 3
7162 NS4B (2354) U  C Leu  Ser 4
7163 NS4B (2354) A  U or C Leu  Phe 7
7182 NS4B (2361) G  A Gly  Ser 2
7546 NS4B (2482) C  U Ala  Val 10
7630 NS5 (2510) A  G Lys  Arg 1
10,275 3 UTR A  U n/ab 6
10,279 3 UTR A  C n/a 4
a Amino acid position in DEN4 polyprotein beginning with the methi-
onine residue of the C protein (nt 102–104) as residue 1.
b Not applicable.
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observed in the 5-FU parent, 1189. The att phenotypes of
5-FU mutant parent viruses, 738, 922, 1081, and 1083,
were similarly attributed to single mutations; NS2A 3540,
NS2B 4306, NS1 2650, and 3-UTR 10634, respectively.
However, two separate mutations (NS2A 3771 and NS3
4891) contributed to the phenotypes of 5-FU mutant virus
1136.
Replication of DEN4 viruses in SCID mice
transplanted with HuH-7 cells
To further examine the in vivo growth properties of the
six 5-FU mutant viruses with mutations in only the NS
genes and/or the 3-UTR and the corresponding 17
rDEN4 mutant viruses, replication was assessed in SCID
mice transplanted with HuH-7 cells (SCID-HuH-7). Pre-
liminary experiments indicated that SCID-HuH-7 mice
inoculated with DEN4 2A-13 directly into the tumor de-
veloped viremia with maximum levels (up to 8.0
log10PFU/ml serum) achieved on Day 6 or 7. Virus could
also be detected in brain, liver, and tumor homogenates
(data not shown). The level of viremia in SCID-HuH-7
mice infected with parental 5-FU or rDEN4 mutant vi-
ruses was compared with that of the parallel-passaged
control virus, 2A-13, or rDEN4, respectively. Results of
TABLE 6
sp, ts, and Mouse Attenuation Phenotypes of rDEN4 Mutant Viruses Encoding Single Mutations Identified in Six sp 5-FU Mutant Viruses
5-FU
mutant
virus Virus
Gene/
region
containing
mutation
Mean virus titer (log10PFU/ml)
at indicated temp (°C)
Replication in
suckling miceb
Replication in
HuH-7-SCID miced
Vero cells HuH-7 cells
n
Mean virus
titer  SE
(log10PFU/g
brain)
Mean
log10-unit
reduction from
value for wtc n
Mean
peak virus
titer  SE
(log10PFU/ml
serum)
Mean
log10-unit
reduction
from value
for wtc35 39 a 35 39 
2A-13 7.6 7.1 0.5 7.8 6.6 1.2 30 6.5 0.1 — 29 6.8 0.2 —
rDEN4 7.6 6.8 0.8 8.0 6.7 1.3 54 5.8 0.1 — 32 6.3 0.2 —
rDEN430 7.6 6.9 0.7 7.7 5.6 2.1 30 5.6 0.1 0.2 18 5.4 0.2 0.9
738 Parent 6.5 5.7 0.8 6.9 f 3.1e 3.8 12 4.4 0.4 2.3 9 5.4 0.7 1.9
rDEN4-3540 NS2A 6.9 5.1 1.8 7.4 3.7 3.7 12 4.1 0.3 1.7 5 6.1 0.3 ()0.1
rDEN4-7162 NS4B 7.2 6.8 0.4 7.4 6.6 0.8 8 5.6 0.3 0.3 5 6.8 0.6 0.3
922 Parent 7.3 3.8 3.5 7.4 f 3.0 4.4 12 3.5 0.1 2.9 6 6.2 0.2 0.4
rDEN4-4306 NS2B 5.0 f 2.2 2.8 5.6 f 1.6 4.0 12 1.7 0.1 4.1 5 5.2 0.6 1.1
rDEN4-5872 NS3 5.7 2.5 3.2 6.5 f 1.6 4.9 12 4.5 0.3 1.3 5 6.2 0.5 0.1
rDEN4-7163 NS4B 7.8 7.2 0.6 8.0 7.4 0.6 6 6.2 0.2 ()0.1 6 5.8 0.6 ()0.2
rDEN4-10279 3 UTR 6.9 5.7 1.2 7.7 5.7 2.0 6 4.8 0.2 0.7 4 6.7 0.2 0.4
1081 Parent 6.9 3.9 3.0 5.8 f 1.9 3.9 12 2.6 0.2 3.9 4 4.2 0.5 2.4
rDEN4-2650 NS1 5.1 3.0 2.1 5.5 f 2.8 2.7 12 3.0 0.3 2.8 6 4.7 0.5 2.2
rDEN4-7163 NS4B 7.8 7.2 0.6 8.0 7.4 0.6 6 6.2 0.2 ()0.1 6 5.8 0.6 ()0.2
1083 Parent 7.4 5.8 1.6 7.4 f 1.6 5.8 12 4.5 0.4 2.0 9 4.4 0.3 2.9
rDEN4-3702 NS2A 6.8 5.6 1.2 7.6 4.7 2.9 18 4.9 0.3 0.9 7 6.3 0.3 0.2
rDEN4-7153 NS4B 7.7 7.2 0.5 8.0 6.9 1.1 6 5.7 0.1 0.2 4 5.9 0.7 0.1
rDEN4-10634 3 UTR 4.9 1.6 3.3 5.7 f 1.6 4.1 12 2.4 0.3 3.4 7 3.3 0.4 3.6
1136 Parent 5.1 1.6 3.5 5.7 f 1.6 4.1 6 2.9 0.3 4.5 7 4.5 0.4 1.2
rDEN4-3771 NS2A 7.0 4.6 2.4 7.6 f 3.7 3.9 12 2.6 0.4 3.2 4 6.4 0.2 ()0.1
rDEN4-4891 NS3 7.1 1.6 5.5 7.4 f 1.6 5.8 12 2.5 0.3 3.5 6 6.0 0.5 0.3
rDEN4-10275 3 UTR 6.9 5.8 1.1 7.1 5.2 1.9 6 5.0 0.3 0.5 4 6.7 0.3 0.4
1189 Parent 6.3 f 3.8 2.5 5.5 f 1.6 3.9 12 3.2 0.4 3.7 13 2.3 0.3 3.8
rDEN4-3303 NS1 6.1 4.8 1.3 6.6 3.9 2.7 8 5.7 0.4 0.2 4 6.3 0.3 0.8
rDEN4-4812 NS3 7.0 6.3 0.7 7.1 6.3 0.8 12 4.8 0.2 1.0 5 6.1 0.5 ()0.5
rDEN4-5097 NS3 5.0 f 1.6 3.4 4.6 f 1.6 3.0 12 1.8 0.1 4.0 8 1.9 0.1 4.3
rDEN4-7182 NS4B 7.7 6.9 0.8 7.8 6.8 1.0 6 6.2 0.1 ()0.1 6 6.3 0.3 ()0.7
a Reduction in mean virus titer (log10PFU/ml) at 39°C compared to permissive temperature (35°C).
b Groups of six suckling mice were inoculated i.c. with 104 PFU of virus. Brains were removed 5 days later, homogenized, and titered in Vero cells.
c Comparison of mean virus titers of mice inoculated with mutant virus and concurrent DEN4 control. Bold denotes 50- or 100-fold decrease
in replication in suckling or SCID-HuH-7 mice, respectively.
d Groups of HuH-7-SCID mice were inoculated directly into the tumor with 104 PFU virus. Serum was collected on day 6 and 7 and titered in Vero
cells.
e Underlined values indicate a 2.5 or 3.5 log10PFU/ml reduction in titer in Vero cells or HuH-7 cells, respectively, at indicated temperature when
compared to permissive temperature (35°C).
f Small plaque size at 35°C; small plaques have a diameter of 1.0 mm compared to wild-type plaque diameter of 1.5–2.0 mm in Vero cells, or a
diameter of 0.4 mm compared to wild-type plaque diameter of 0.75 to 1.0 mm in HuH-7 cells.
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four separate experiments indicated that the vaccine
candidate, rDEN430, had an almost 10-fold reduction in
virus replication compared to wild-type rDEN4 (Table 6).
Three 5-FU mutant viruses had a greater than 100-fold
reduction in viremia in the SCID-HuH-7 mice compared
to wild-type 2A-13 virus: 1081, 1083, and 1189. Analysis of
the genetic basis of the att phenotype in these parent
5-FU mutant viruses identified three individual mutations
in NS1, NS3, and the 3-UTR which conferred at least a
100-fold reduction in viremia. Specifically, rDEN4-2650
(NS1), rDEN4-5097 (NS3), and rDEN4-10634 (3-UTR)
manifested a 2.2, 3.6, and 4.3 log10PFU/ml reduction in
peak titer of viremia compared to rDEN4, respectively.
These mutations also conferred the att phenotype in
suckling mouse brain.
Conservation of att mutations in DEN1, -2, and -3
Based on the moderate genetic homology of the four
DEN virus serotypes, it was of interest to determine
whether the sites of the att mutations identified in DEN4
are conserved in DEN1, -2, and/or -3. The phenotypes
and amino acid or UTR nucleotide conservation at the
seven specific mutant loci which conferred an att phe-
notype in suckling mouse brain or SCID-HuH-7 mice are
summarized in Table 7. The wild-type DEN4 virus se-
quence at six of the seven mutant loci was at a con-
served site in at least two DEN virus serotypes, and four
were conserved in all serotypes. Each of the mutations
that restricted replication in the SCID-HuH-7 mice (2650
in NS1, 5097 in NS3, 10634 in the 3-UTR) was at a
conserved site in each of the four DEN virus serotypes.
DISCUSSION
As part of a molecular genetic vaccine strategy, we
sought to develop attenuating mutations that might be
useful in the development of a live-attenuated tetravalent
dengue virus vaccine. Specifically, mutations which re-
strict replication of the vaccine virus in human liver cells
were generated since there was some residual virulence
of the rDEN430 vaccine candidate for the liver of hu-
mans. Mutant viruses with a sp phenotype were sought
in both Vero cells and HuH-7 human liver cells to identify
host-range mutant viruses that were specifically re-
stricted in replication in HuH-7 cells (sp in HuH-7 but not
in Vero). Such mutations might be particularly useful in
limiting replication of a candidate vaccine in the liver of
vaccinees while preserving both efficient replication in
Vero cells and immunogenicity in vivo.
Several observations from the present study indicate
that sp mutations confer an att phenotype in vivo. This is
not surprising since attenuation in suckling mouse brain
has been reported for live DEN virus vaccine candidates
possessing sp phenotypes, including the DEN2 PDK-53
and DEN2 PR-159/S-1 vaccine strains (Bhamarapravati
and Yoksan, 1997; Butrapet et al., 2000; Eckels et al.,
1980; Innis et al., 1988). Each of 22 DEN4 5-FU mutant
viruses with a sp phenotype (some of which were also ts)
in either Vero or HuH-7 cells manifested restricted rep-
lication in the brains of mice. Six 5-FU mutant viruses
with a sp phenotype in the absence of a ts phenotype
were more attenuated in the brains of suckling mice than
mutant viruses with solely a ts phenotype, suggesting
that the sp phenotype specifies a greater level of atten-
uation for mouse brain than does the ts phenotype.
Sixteen mutant viruses with both a ts and a sp phenotype
had an even greater reduction in replication (Tables 1
and 2), further suggesting that the attenuation conferred
by the ts and sp phenotypes can be additive. Importantly,
17 of the 22 spmutant viruses were host-range spmutant
viruses, being sp only in HuH-7 cells. Since such muta-
TABLE 7
Conservation of the att Mutations Identified in rDEN4 Viruses within the DEN1, DEN2, and DEN3 Virus Serotypes
Mutation (nt number) Amino acid changea Gene/region
Mouse att phenotypesb Identity in DEN serotypec
Suckling brain SCID-HuH-7 serum 1 (WP) 2 (NGC) 3 (H87)
2650 N850S NS1     
3540 E1147K NS2A     
3771 R1224G NS2A     
4306 N1402S NS2B     
4891 I1597T NS3     
5097 D1666N NS3     
10634 n/a 3 UTR     
a Amino acid position in DEN4 polyprotein beginning with the methionine residue of the C protein (nt 102–104) as residue 1. Wild-type amino acid
on left of amino acid position; mutant amino acid on right.
b att replication in suckling mouse brain defined as 50-fold decrease in virus titer in brain on day 5 postinfection when compared to wild-type
rDEN4. att replication in SCID-HuH-7 mice defined as a 100-fold decrease in peak serum virus titer on day 6 and 7 postinfection when compared
to wild-type rDEN4.
c Plus indicates presence of exact DEN4 wild-type amino acid or nucleotide (UTR) in other serotypes. Minus indicates the amino acid or nt of DEN4
wild-type is not identical in the other serotypes. Strains: DEN1 Western Pacific, DEN2 New Guinea C, DEN3 H87.
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tions could potentially be useful in restricting the repli-
cation of a DEN4 virus in human liver cells, we used
nucleotide sequence analysis to determine the genetic
basis of the sp phenotype.
Analysis of the complete genomic sequence of the 22
sp DEN4 viruses revealed substitutions in the 3-UTR as
well as coding mutations in all genes except NS4A. It
was first noted that several specific mutations were
present in two or more of the 22 sp DEN4 mutant viruses
and that many of these same mutations were also pre-
viously identified among the set of 20 ts DEN4 mutant
viruses (Blaney et al., 2001). Since flaviviruses can rap-
idly accumulate mutations during passage in tissue cul-
ture (Dunster et al., 1999; Mandl et al., 2001), many of
these overrepresented mutations, previously referred to
as putative Vero cell adaptation mutations (Blaney et al.,
2001), likely promote efficient replication in Vero cells
and were selected unintentionally during the biological
cloning of the mutant viruses. The effect of these muta-
tions on DEN virus replication in Vero cells, the proposed
substrate for vaccine manufacture, is currently being
evaluated.
It was next noted that six of the 22 sp DEN4 virus
mutant viruses contained coding mutations in only the
NS genes and/or nucleotide substitutions in the 3-UTR,
and that five of these six viruses had a host-range sp
phenotype. Such mutations are particularly well suited
for construction of chimeric viruses consisting of an
attenuated DEN4 genetic background bearing the wild-
type structural genes of another DEN virus serotype
(Bray and Lai, 1991; Durbin et al., 2001; Huang et al.,
2000) or of another flavivirus such as West Nile virus
(WNV) or Langat virus (LAN) (Pletnev and Men, 1998;
Pletnev et al., 2002). For this reason we focused our
attention on determining the genetic basis of the sp
phenotype of these six viruses which contained a total of
17 different mutations. rDEN4 viruses were engineered
that contained each of these mutations as separate mu-
tations, and the cell culture and in vivo phenotypes of the
17 rDEN4 viruses were then determined. Seven of these
mutations were identified as attenuating mutations that
conferred restricted replication in suckling mouse brain
ranging from 50-fold to 10,000-fold below that observed
in mice infected with wild-type rDEN4.
We next sought to determine whether any of the six
5-FU mutant viruses bearing mutations in only the NS
genes and UTR or if any of their 17 rDEN4 single-muta-
tion derivatives were restricted in replication in the liver
of an infected animal. Since DEN viruses replicate poorly
in the liver of mice and corresponding studies are im-
practical to conduct in nonhuman primates, an animal
model that evaluates the in vivo level of replication of
DEN virus in liver cells was developed based on a recent
report examining the replication of DEN virus in SCID
mice transplanted with a continuous cell line of human
liver tumor cells (An et al., 1999). SCID mice transplanted
with human continuous cell lines, primary cells, or orga-
nized tissues have similarly been used to study the
replication of other viruses which lack a suitable small
animal model (Mosier, 2000). In our study, SCID mice
were transplanted with HuH-7 cells since DEN4 virus
replicated efficiently in these cells in tissue culture and
since these were the cells used to define the host-range
phenotype. Although each of the six 5-FU mutant viruses
evaluated in SCID-HuH-7 mice had an sp phenotype in
HuH-7 cells, only three viruses manifested reduced rep-
lication in these mice. This observation indicated that
analysis of virus replication in SCID-HuH-7 mice served
as a more stringent test to define the att phenotype in
these liver cells compared to the sp phenotype in cell
culture.
An analysis of the genetic basis of the phenotypes
specified by the mutations in the 5-FU mutant viruses
that manifested restricted replication in SCID-HuH-7
mice indicated that (1) three separate mutations con-
ferred the att phenotype; (2) these mutations were lo-
cated in two proteins, NS1 and NS3, and in the 3-UTR;
(3) these three mutations were fully responsible for each
of the cell culture (ts or sp) and in vivo (attenuation in
mouse brain and SCID-HuH-7 mice) phenotypes of the
parent viruses; and (4) two of the three mutations (2650
and 10634) specify the host-range sp phenotype (sp on
HuH-7 only) and might therefore be particularly useful in
a vaccine virus. Although the relevance of such SCID-
transplant models to virus replication and disease in
humans is unknown, the identification of three novel
mutations which restrict DEN4 virus replication in SCID-
HuH-7 mice will allow us to examine the correlation
between the att phenotype in SCID-HuH-7 mice with that
in rhesus monkeys or humans. Such mutations, specifi-
cally the host-range sp mutations, might be useful in
conjunction with the 30 mutation to decrease the re-
sidual virulence of rDEN430 for the human liver, and
studies are in progress to construct such rDEN4 viruses
and evaluate them in monkeys and humans.
The present studies have not elucidated the mecha-
nisms by which the three sp mutations restrict DEN4
replication in cell culture and suckling or SCID-HuH-7
mice, although previous studies of NS1, NS3, and the
3-UTR may yield potential insights (Rice, 1996). Previ-
ously, we described a ts-attenuating mutation at nucleo-
tide 4995 in NS3, resulting in a substitution at amino acid
158 located in the N-terminal half of the protein which
contains the protease domain (Blaney et al., 2001). How-
ever, the sp mutation 5097 described in this study, which
results in an amino acid substitution (Asp to Asn) at
position 192 of NS3, is localized in conserved motif I
(amino acid 188–205) of the C-terminal region containing
the nucleoside triphosphatase (NTPase) and RNA heli-
case domains (Gorbalenya et al., 1990; Kadare and
Haenni, 1997; Kim et al., 1998; Li et al., 1999). This motif,
involved in binding the  and  phosphate groups of NTP,
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is highly conserved in flaviviruses and the Asp at amino
acid position 192 is conserved in DEN1–4, YF, WNV, LAN,
Kunjin virus, Japanese encephalitis virus, tick-borne en-
cephalitis virus, and Powasson virus (Chang, 1997). Two
substitutions in motif I have previously been shown to
abolish ATPase and RNA helicase activities (Matusan et
al., 2001), suggesting that the 5097 mutation may behave
similarly. It is possible that the two mutations in NS3,
namely, the 4995 and 5097 mutations which are present
in distinct functional domains of NS3, could be combined
using reverse genetics to yield a new rDEN4 virus, per-
haps with a synergistic effect on the att phenotype.
The mutation at nucleotide 2650 results in an amino
acid substitution (Asn to Ser) at position 76 of NS1, a 352
amino acid glycosylated dimer which localizes to intra-
cellular membranes, the cell surface, and is also present
in a secreted form (Brandt et al., 1970; Mackenzie et al.,
1996; Muylaert et al., 1997; Rice, 1996). The mechanism
of the phenotype specified by this mutation cannot be
inferred at this time. Interestingly, the final sp mutation
which conferred an att phenotype in SCID-HuH-7 mice
results in a noncoding change in the 3-UTR at nucleo-
tide 10,634 (U to C). Substitution or deletion att mutations
have been found in the noncoding regions of flaviviruses
(Butrapet et al., 2000; Cahour et al., 1995; Mandl et al.,
1998; Men et al., 1996; Pletnev, 2001), as well as the
Sabin poliovirus vaccine strains (Macadam et al., 1994)
and respiratory syncytial virus (Whitehead et al., 1998).
The 10,634 mutation is located 15 nt from the 3-terminus
of the genome and is not paired to a complementary
nucleotide in the predicted stem-loop secondary struc-
ture (Proutski et al., 1997; Shurtleff et al., 2001). Mutations
in the 3-UTR could possibly restrict replication by mul-
tiple mechanisms including alterations in the secondary
structure which could abrogate binding of viral or cellular
factors required for efficient RNA synthesis or interfer-
ence with RNA packaging in virion assembly.
The sp mutations identified among the 5-FU mutant
viruses could potentially be used in several different
approaches for the development of DEN virus vaccine
strains. As described above for the generation of anti-
genic chimeric viruses, one or more sp attenuating mu-
tations could be evaluated in the context of the DEN430
genetic background as a means to augment the att
phenotype in humans already conferred by the 30 mu-
tation. A second approach would be to introduce a sp-
attenuating mutation, with or without 30, into infectious
cDNA clones of the other three DEN serotypes. The
ability to transfer mutations among genetically related
viruses and maintain similar att phenotypes has been
previously demonstrated (Skiadopoulos et al., 1999). In-
terestingly, six of seven mutations with att phenotypes in
suckling mouse brain were found to be conserved in at
least two DEN virus serotypes (Table 7), suggesting that
one or more of these mutations could be used to atten-
uate DEN1, -2, and -3 virus. Importantly, the amino acid
and nucleotide sequence of each of the mutations in
DEN4 NS1, NS3, and the 3-UTR with an att phenotype in
SCID-HuH-7 mice are conserved among the other three
DEN virus serotypes. These distinct strategies could
potentially be used as separate or complementary ap-
proaches to the construction of a tetravalent DEN virus
vaccine, underlining the importance of the identification
of a large panel of att mutations within the DEN viruses.
MATERIALS AND METHODS
Cells and viruses
WHO Vero cells (African green monkey kidney cells)
were grown in MEM (Invitrogen, Grand Island, NY) sup-
plemented with 10% fetal bovine serum (FBS) (Invitro-
gen), 2 mM L-glutamine (Invitrogen), and 0.05 mg/ml
gentamicin (Invitrogen). HuH-7 cells (human hepatoma
cells) (Nakabayashi et al., 1982) were maintained in D-
MEM/F-12 (Invitrogen) supplemented with 10% FBS, 1
mM L-glutamine, and 0.05 mg/ml gentamicin.
DEN4 2A virus is a wild-type virus derived from a
cDNA clone of DEN4 strain 814669 (Dominica, 1981) (Lai
et al., 1991; Mackow et al., 1987). The nucleotide se-
quence of DEN4 2A, the parent of the 5-FU mutant
viruses, was previously assigned GenBank Accession
No. AF375822 (Blaney et al., 2001). The DEN4 vaccine
candidate, 2A30 (Durbin et al., 2001), contains a 30-nt
deletion in the 3-UTR which removes nucleotides
10,478–10,507 (Men et al., 1996). The cDNA clones p4, a
modified derivative of the DEN4 2A cDNA clone, and
p430 were used to generate recombinant wild-type and
attenuated viruses, rDEN4 and rDEN430, respectively
(Durbin et al., 2001). GenBank accession numbers were
previously assigned as follows (virus: Accession No.):
DEN4 strain 814669: AF326573; 2A30: AF326826;
rDEN4: AF326825; rDEN430: AF326827.
Generation and biological cloning of mutant viruses
with a sp phenotype
The generation of 1248 virus clones from a pool of
5-fluorouracil-mutagenized DEN4 2A has been previ-
ously described (Blaney et al., 2001). Briefly, monolayers
of Vero cells were infected with DEN4 2A at a multiplicity
of infection (m.o.i.) of 0.01 and overlaid with MEM sup-
plemented with 2% FBS and 1 mM 5-FU (Sigma, St. Louis,
MO), which reduced replication of DEN4 2A 100-fold.
Vero cells in 96-well plates were inoculated with the
5-FU-treated virus suspension, and virus clones were
harvested from plates receiving terminally diluted virus.
A total of 1248 virus clones were generated from the
cultures treated with 1 mM 5-FU. Two virus clones, 2A-1
and 2A-13, were generated in the same manner from
control cultures not treated with 5-FU and served as
parallel-passaged control viruses with a wild-type phe-
notype.
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Evaluation of in vitro plaque size and temperature
sensitivity
The 1248 5-FU-mutagenized virus clones were
screened for temperature sensitivity by assessing vi-
rus replication at 35°C (permissive temperature) and
39°C (restrictive temperature) in Vero and HuH-7 cells.
Cell monolayers in 96-well plates were inoculated with
serial 10-fold dilutions of virus and replicate plates
were incubated at 35 and 39°C for five days in tem-
perature-controlled water baths. Virus replication was
determined by immunoperoxidase staining as previ-
ously described (Blaney et al., 2001). A collection of
193 5-FU virus clones demonstrated a 100-fold or
greater reduction in titer at 39°C in either cell line, and
these presumptive ts viruses were further character-
ized. The efficiency of plaque formation (EOP) at per-
missive and restrictive temperatures and the plaque
size of each of the 193 virus clones were determined
as follows. Serial 10-fold dilutions of virus suspension
were inoculated onto confluent Vero cell and HuH-7
cell monolayers in replicate 24-well plates. After incu-
bation at 35°C for 2 h, monolayers were overlaid with
0.8% methylcellulose (EM Science, Gibbstown, NJ) in
L-15 medium (Quality Biologicals, Gaithersburg, MD)
supplemented with 2% FBS, gentamicin, and L-glu-
tamine. After incubation of replicate plates for 5 days
at 35, 37, 38, or 39°C in temperature-controlled water
baths, plaques were visualized by immunoperoxidase
staining and counted as previously described. Plaque
size of each of the 193 viruses was evaluated at the
permissive temperature (35°C) and compared to that
of DEN4 2A-13 parallel-passaged control virus with a
wild-type plaque size. Mutant viruses incubated at the
permissive temperature of 35°C which had a plaque
size 1 or 0.4 mm (approximately 50% the size of
wild-type DEN4 2A-13) in Vero or HuH-7 cells, respec-
tively, were designated as having a sp phenotype. The
level of temperature sensitivity and plaque size of
each virus was confirmed in at least two separate
experiments. Seventy-five viruses which were con-
firmed to have a putative ts and/or sp phenotype were
biologically cloned an additional two times and phe-
notypes were reassessed. Twenty-two of the 75 termi-
nally diluted viruses were found to have a sp pheno-
type. Sixteen of the 22 sp mutant viruses were also
found to have a ts phenotype as defined by a 2.5 or 3.5
log10PFU/ml reduction in virus titer in Vero or HuH-7
cells, respectively, at restrictive temperature com-
pared to the permissive temperature of 35°C, as pre-
viously described (Blaney et al., 2001). Twenty of the
75 terminally diluted viruses were found to have a ts
phenotype without a sp phenotype and were previ-
ously described (Blaney et al., 2001). The remainder of
the 75 viruses did not meet either criteria for a ts or sp
mutant virus.
Evaluation of sp mutant viruses for restricted
replication in suckling mice and SCID mice
transplanted with HuH-7 cells
Animal experiments were carried out in accordance
with the regulations and guidelines of the National Insti-
tutes of Health, Bethesda, MD. Growth of DEN4 5-FU
mutant viruses was determined in Swiss Webster suck-
ling mice (Taconic Farms, Germantown, NY). Groups of
six seven-day-old mice were inoculated intracerebrally
with 104 PFU of virus in 30 l Opti-MEM I (Invitrogen) and
the brain of each mouse was removed 5 days later and
individually analyzed as previously described (Blaney et
al., 2001). Clarified supernatants of 10% suspensions of
mouse brain were frozen at 70°C, and the virus titer
was determined by plaque assay in Vero cells.
For analysis of DEN4 virus replication in SCID-HuH-7
mice, four- to six-week-old SCID mice (Tac:Icr:Ha(ICR)-
Prkdcscid) (Taconic Farms) were injected intraperitoneally
with 107 HuH-7 cells suspended in 200 l phosphate-
buffered saline (PBS). For transplantation, HuH-7 cells
were propagated in cell culture as described above and
harvested by trypsinization at approximately 80% conflu-
ence. Cells were washed twice in PBS, counted, resus-
pended in an appropriate volume of PBS, and injected
into mice. Tumors were detected in the peritoneum five
to six weeks after transplantation, and only mice with
apparent tumors were used for inoculation. Mice were
infected by direct inoculation into the tumor with 104 PFU
of virus in 50 l Opti-MEM I. Mice were monitored daily
for 7 days and serum for virus titration was obtained by
tail-nicking on Day 6 and 7. Approximately 400 l blood
was collected in a serum separator tube (Sarstedt, Ger-
many) and centrifuged, and serum was aliquoted and
stored at 70°C. The virus titer was determined by
plaque assay in Vero cells. Seven days after infection,
most mice developed morbidity and all mice were sac-
rificed. Tumors were excised and weighed to confirm
uniformity of the experimental groups.
Determination of the complete genomic sequence of
the sp mutant viruses
The nucleotide sequence of the 5-FU-mutagenized
DEN4 viruses was determined as described previously
(Durbin et al., 2001). Briefly, genomic RNA was isolated
from virus clones and cDNA was prepared by reverse
transcription and served as template for the generation
of overlapping PCR fragments. A panel of primers was
designed to sequence both strands of the PCR product
from which consensus sequences were assembled and
analyzed. The nucleotide sequence of the 5 and 3
regions of the virus genome was determined after circu-
larization of the RNA genome as previously described
(Durbin et al., 2001).
136 BLANEY ET AL.
Generation of recombinant DEN4 viruses
Cloning and transfection of full-length DEN4 cDNA
clones were performed as previously described (Blaney
et al., 2001). Briefly, 500 to 2000 nucleotide fragments of
the DEN4 cDNA clone, p4, were subcloned into a mod-
ified pUC119 vector and point mutations were introduced
by site-directed mutagenesis and confirmed by se-
quence analysis. Full-length RNA transcripts were gen-
erated by in vitro transcription of the mutagenized p4
cDNA clones using the AmpliCap SP6 message maker
kit (Epicentre Technologies, Madison, WI). C6/36 cells
were transfected with RNA combined with DOTAP lipo-
somal transfection reagent (Roche, Indianapolis, IN), and
cell culture media were harvested 5 to 7 days later.
Recovered viruses were terminally diluted twice and
propagated in Vero cells. Recombinant DEN4 viruses are
designated rDEN4—followed by the nucleotide position
of the incorporated mutation.
ACKNOWLEDGMENTS
We thank Dr. Kathryn Hanley, Dr. Alexander Schmidt, and Dr. Robert
Chanock for careful review of this manuscript and for suggestions.
REFERENCES
An, J., Kimura-Kuroda, J., Hirabayashi, Y., and Yasui, K. (1999). Develop-
ment of a novel mouse model for dengue virus infection. Virology
263(1), 70–77.
Bancroft, W. H., Scott, R. M., Eckels, K. H., Hoke, C. H., Jr., Simms, T. E.,
Jesrani, K. D., Summers, P. L., Dubois, D. R., Tsoulos, D., and Russell,
P. K. (1984). Dengue virus type 2 vaccine: Reactogenicity and immu-
nogenicity in soldiers. J. Infect. Dis. 149(6), 1005–1010.
Bhamarapravati, N., and Sutee, Y. (2000). Live attenuated tetravalent
dengue vaccine. Vaccine 18(Suppl. 2), 44–47.
Bhamarapravati, N., and Yoksan, S. (1997). Live attenuated tetravalent
dengue vaccine. In “Dengue and Dengue Hemorrhagic Fever” (D. J.
Gubler, and G. Kuno, Eds.), pp. 367–377. CAB International, New York.
Blaney, J. E., Jr., Johnson, D. H., Firestone, C. Y., Hanson, C. T., Murphy,
B. R., and Whitehead, S. S. (2001). Chemical mutagenesis of dengue
virus type 4 yields mutant viruses which are temperature sensitive in
vero cells or human liver cells and attenuated in mice. J. Virol. 75(20),
9731–9740.
Brandt, W. E., Chiewslip, D., Harris, D. L., and Russell, P. K. (1970).
Partial purification and characterization of a dengue virus soluble
complement-fixing antigen. J. Immunol. 105(6), 1565–1568.
Bray, M., and Lai, C. J. (1991). Construction of intertypic chimeric
dengue viruses by substitution of structural protein genes. Proc. Natl.
Acad. Sci. USA 88(22), 10342–10346.
Burke, D. S., Nisalak, A., Johnson, D. E., and Scott, R. M. (1988). A
prospective study of dengue infections in Bangkok. Am. J. Trop. Med.
Hyg. 38(1), 172–180.
Butrapet, S., Huang, C. Y., Pierro, D. J., Bhamarapravati, N., Gubler, D. J.,
and Kinney, R. M. (2000). Attenuation markers of a candidate dengue
type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations
in the 5 noncoding region and nonstructural proteins 1 and 3. J. Virol.
74(7), 3011–3019.
Cahour, A., Pletnev, A., Vazielle-Falcoz, M., Rosen, L., and Lai, C. J.
(1995). Growth-restricted dengue virus mutants containing deletions
in the 5 noncoding region of the RNA genome. Virology 207(1),
68–76.
Chang, G.-J. (1997). Molecular biology of dengue viruses. In “Dengue
and Dengue Hemorrhagic Fever” (D. J. Gubler, and G. Kuno, Eds.), pp.
175–198. CAB International, New York.
Couvelard, A., Marianneau, P., Bedel, C., Drouet, M. T., Vachon, F.,
Henin, D., and Deubel, V. (1999). Report of a fatal case of dengue
infection with hepatitis: Demonstration of dengue antigens in hepa-
tocytes and liver apoptosis. Hum. Pathol. 30(9), 1106–1110.
Crowe, J. E., Jr., Bui, P. T., Davis, A. R., Chanock, R. M., and Murphy, B. R.
(1994a). A further attenuated derivative of a cold-passaged temper-
ature-sensitive mutant of human respiratory syncytial virus retains
immunogenicity and protective efficacy against wild-type challenge
in seronegative chimpanzees. Vaccine 12(9), 783–790.
Crowe, J. E., Jr., Bui, P. T., London, W. T., Davis, A. R., Hung, P. P.,
Chanock, R. M., and Murphy, B. R. (1994b). Satisfactorily attenuated
and protective mutants derived from a partially attenuated cold-
passaged respiratory syncytial virus mutant by introduction of addi-
tional attenuating mutations during chemical mutagenesis. Vaccine
12(8), 691–699.
Dunster, L. M., Wang, H., Ryman, K. D., Miller, B. R., Watowich, S. J.,
Minor, P. D., and Barrett, A. D. (1999). Molecular and biological
changes associated with HeLa cell attenuation of wild-type yellow
fever virus. Virology 261(2), 309–318.
Durbin, A. P., Karron, R. A., Sun, W., Vaughn, D. W., Reynolds, M. J.,
Perreault, J. R., Thumar, B., Men, R., Lai, C. J., Elkins, W. R., Chanock,
R. M., Murphy, B. R., and Whitehead, S. S. (2001). Attenuation and
immunogenicity in humans of a live dengue virus type-4 vaccine
candidate with a 30 nucleotide deletion in its 3-untranslated region.
Am. J. Trop. Med. Hyg. 65(5), 405–413.
Eckels, K. H., Harrison, V. R., Summers, P. L., and Russell, P. K. (1980).
Dengue-2 vaccine: Preparation from a small-plaque virus clone.
Infect. Immunol. 27(1), 175–180.
Eckels, K. H., Scott, R. M., Bancroft, W. H., Brown, J., Dubois, D. R.,
Summers, P. L., Russell, P. K., and Halstead, S. B. (1984). Selection of
attenuated dengue 4 viruses by serial passage in primary kidney
cells. V. Human response to immunization with a candidate vaccine
prepared in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 33(4),
684–689.
Edelman, R., Tacket, C. O., Wasserman, S. S., Vaughn, D. W., Eckels,
K. H., Dubois, D. R., Summers, P. L., and Hoke, C. H. (1994). A live
attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary
dog kidney cell culture is attenuated and immunogenic for humans.
J. Infect. Dis. 170(6), 1448–1455.
Gorbalenya, A. E., Koonin, E. V., and Wolf, Y. I. (1990). A new superfamily
of putative NTP-binding domains encoded by genomes of small DNA
and RNA viruses. FEBS Lett. 262(1), 145–148.
Gubler, D. J. (1998). Dengue and dengue hemorrhagic fever. Clin.
Microbiol. Rev. 11(3), 480–496.
Gubler, D. J., and Meltzer, M. (1999). Impact of dengue/dengue hemor-
rhagic fever on the developing world. Adv. Virus Res. 53, 35–70.
Guirakhoo, F., Arroyo, J., Pugachev, K. V., Miller, C., Zhang, Z. X., Weltzin,
R., Georgakopoulos, K., Catalan, J., Ocran, S., Soike, K., Ratterree, M.,
and Monath, T. P. (2001). Construction, safety, and immunogenicity in
nonhuman primates of a chimeric yellow fever-dengue virus tetrava-
lent vaccine. J. Virol. 75(16), 7290–7304.
Guirakhoo, F., Weltzin, R., Chambers, T. J., Zhang, Z. X., Soike, K.,
Ratterree, M., Arroyo, J., Georgakopoulos, K., Catalan, J., and Monath,
T. P. (2000). Recombinant chimeric yellow fever-dengue type 2 virus
is immunogenic and protective in nonhuman primates. J. Virol. 74(12),
5477–5485.
Halstead, S. B., O’Rourke, E. J., and Allison, A. C. (1977). Dengue viruses
and mononuclear phagocytes. II. Identity of blood and tissue leuko-
cytes supporting in vitro infection. J. Exp. Med. 146(1), 218–229.
Hanley, K. A., Lee, J. J., Blaney, J. E., Jr., Murphy, B. R., and Whitehead,
S. S. (2002). Paired charge-to-alanine mutagenesis of dengue virus
type 4 NS5 generates mutants with temperature-sensitive, host
range, and mouse attenuation phenotypes. J. Virol. 76(2), 525–531.
Huang, C. Y., Butrapet, S., Pierro, D. J., Chang, G. J., Hunt, A. R.,
137SMALL-PLAQUE DENGUE VIRUS MUTANTS
Bhamarapravati, N., Gubler, D. J., and Kinney, R. M. (2000). Chimeric
dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a
potential candidate dengue type 1 virus vaccine. J. Virol. 74(7), 3020–
3028.
Huerre, M. R., Lan, N. T., Marianneau, P., Hue, N. B., Khun, H., Hung,
N. T., Khen, N. T., Drouet, M. T., Huong, V. T., Ha, D. Q., Buisson, Y.,
and Deubel, V. (2001). Liver histopathology and biological correlates
in five cases of fatal dengue fever in Vietnamese children. Virchows
Arch. 438(2), 107–115.
Innis, B. L. (1995). Dengue and dengue hemorrhagic fever. In “Exotic
Viral Infections” (J. S. Porterfield, Ed.), pp. 103–146. Chapman and
Hall, London.
Innis, B. L., Eckels, K. H., Kraiselburd, E., Dubois, D. R., Meadors, G. F.,
Gubler, D. J., Burke, D. S., and Bancroft, W. H. (1988). Virulence of a
live dengue virus vaccine candidate: A possible new marker of
dengue virus attenuation. J. Infect. Dis. 158(4), 876–880.
Kadare, G., and Haenni, A. L. (1997). Virus-encoded RNA helicases.
J. Virol. 71(4), 2583–2590.
Kalayanarooj, S., Vaughn, D. W., Nimmannitya, S., Green, S., Suntaya-
korn, S., Kunentrasai, N., Viramitrachai, W., Ratanachu-eke, S., Kiat-
polpoj, S., Innis, B. L., Rothman, A. L., Nisalak, A., and Ennis, F. A.
(1997). Early clinical and laboratory indicators of acute dengue ill-
ness. J. Infect. Dis. 176(2), 313–321.
Kanesa-thasan, N., Sun, W., Kim-Ahn, G., Van Albert, S., Putnak, J. R.,
King, A., Raengsakulsrach, B., Christ-Schmidt, H., Gilson, K., Zahrad-
nik, J. M., Vaughn, D. W., Innis, B. L., Saluzzo, J. F., and Hoke, C. H., Jr.
(2001). Safety and immunogenicity of attenuated dengue virus vac-
cines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179–3188.
Kim, J. L., Morgenstern, K. A., Griffith, J. P., Dwyer, M. D., Thomson, J. A.,
Murcko, M. A., Lin, C., and Caron, P. R. (1998). Hepatitis C virus NS3
RNA helicase domain with a bound oligonucleotide: The crystal
structure provides insights into the mode of unwinding. Structure
6(1), 89–100.
Kuo, C. H., Tai, D. I., Chang-Chien, C. S., Lan, C. K., Chiou, S. S., and
Liaw, Y. F. (1992). Liver biochemical tests and dengue fever. Am. J.
Trop. Med. Hyg. 47(3), 265–270.
Lai, C. J., Zhao, B. T., Hori, H., and Bray, M. (1991). Infectious RNA
transcribed from stably cloned full-length cDNA of dengue type 4
virus. Proc. Natl. Acad. Sci. USA 88(12), 5139–5143.
Li, H., Clum, S., You, S., Ebner, K. E., and Padmanabhan, R. (1999). The
serine protease and RNA-stimulated nucleoside triphosphatase and
RNA helicase functional domains of dengue virus type 2 NS3 con-
verge within a region of 20 amino acids. J. Virol. 73(4), 3108–3116.
Lin, Y. L., Liao, C. L., Chen, L. K., Yeh, C. T., Liu, C. I., Ma, S. H., Huang,
Y. Y., Huang, Y. L., Kao, C. L., and King, C. C. (1998). Study of Dengue
virus infection in SCID mice engrafted with human K562 cells. J. Virol.
72(12), 9729–9737.
Macadam, A. J., Stone, D. M., Almond, J. W., and Minor, P. D. (1994). The
5 noncoding region and virulence of poliovirus vaccine strains.
Trends Microbiol. 2(11), 449–454.
Mackenzie, J. M., Jones, M. K., and Young, P. R. (1996). Immunolocal-
ization of the dengue virus nonstructural glycoprotein NS1 suggests
a role in viral RNA replication. Virology 220(1), 232–240.
Mackow, E., Makino, Y., Zhao, B. T., Zhang, Y. M., Markoff, L., Buckler-
White, A., Guiler, M., Chanock, R., and Lai, C. J. (1987). The nucleotide
sequence of dengue type 4 virus: Analysis of genes coding for
nonstructural proteins. Virology 159(2), 217–228.
Mandl, C. W., Holzmann, H., Meixner, T., Rauscher, S., Stadler, P. F.,
Allison, S. L., and Heinz, F. X. (1998). Spontaneous and engineered
deletions in the 3 noncoding region of tick-borne encephalitis virus:
Construction of highly attenuated mutants of a flavivirus. J. Virol.
72(3), 2132–2140.
Mandl, C. W., Kroschewski, H., Allison, S. L., Kofler, R., Holzmann, H.,
Meixner, T., and Heinz, F. X. (2001). Adaptation of tick-borne enceph-
alitis virus to bhk-21 cells results in the formation of multiple heparan
sulfate binding sites in the envelope protein and attenuation in vivo.
J. Virol. 75(12), 5627–5637.
Matusan, A. E., Pryor, M. J., Davidson, A. D., and Wright, P. J. (2001).
Mutagenesis of the Dengue virus type 2 NS3 protein within and
outside helicase motifs: Effects on enzyme activity and virus repli-
cation. J. Virol. 75(20), 9633–9643.
McKee, K. T., Jr., Bancroft, W. H., Eckels, K. H., Redfield, R. R., Summers,
P. L., and Russell, P. K. (1987). Lack of attenuation of a candidate
dengue 1 vaccine (45AZ5) in human volunteers. Am. J. Trop. Med.
Hyg. 36(2), 435–442.
Men, R., Bray, M., Clark, D., Chanock, R. M., and Lai, C. J. (1996). Dengue
type 4 virus mutants containing deletions in the 3 noncoding region
of the RNA genome: Analysis of growth restriction in cell culture and
altered viremia pattern and immunogenicity in rhesus monkeys.
J. Virol. 70(6), 3930–3937.
Mohan, B., Patwari, A. K., and Anand, V. K. (2000). Hepatic dysfunction
in childhood dengue infection. J. Trop. Pediatr. 46(1), 40–43.
Monath, T., and Heinz, F. (1996). Flaviviruses. In “Fields Virology” (D. M.
Knipe, B. N. Fields, P.M. Howley, et al., Eds.), 3rd ed., pp. 961–1034.
Lippincott-Raven, Philadelphia.
Mosier, D. E. (2000). Human xenograft models for virus infection. Virol-
ogy 271(2), 215–219.
Murphy, B. R., and Chanock, R. M. (2001). Immunization against viral
diseases. In “Fields Virology” (D. M. Knipe, P. M. Howley, D. E. Griffin,
R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Strauss, Eds.), Vol. 1,
pp. 435–468. 2 vols. Lippincott Williams & Wilkins, Philadelphia.
Muylaert, I. R., Galler, R., and Rice, C. M. (1997). Genetic analysis of the
yellow fever virus NS1 protein: Identification of a temperature-sen-
sitive mutation which blocks RNA accumulation. J. Virol. 71(1), 291–
298.
Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato, J. (1982).
Growth of human hepatoma cells lines with differentiated functions
in chemically defined medium. Cancer Res. 42(9), 3858–3863.
Pletnev, A. G. (2001). Infectious cDNA clone of attenuated Langat
tick-borne flavivirus (strain E5) and a 3 deletion mutant constructed
from it exhibit decreased neuroinvasiveness in immunodeficient
mice. Virology 282(2), 288–300.
Pletnev, A. G., and Men, R. (1998). Attenuation of the Langat tick-borne
flavivirus by chimerization with mosquito-borne flavivirus dengue
type 4. Proc. Natl. Acad. Sci. USA 95(4), 1746–1751.
Pletnev, A. G., Putnak, R., Speicher, J., Wagar, E. J., and Vaughn, D. W.
(2002). West Nile virus/dengue type 4 virus chimeras that are re-
duced in neurovirulence and peripheral virulence without loss of
immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA
99(5), 3036–3041.
Proutski, V., Gould, E. A., and Holmes, E. C. (1997). Secondary structure
of the 3 untranslated region of flaviviruses: Similarities and differ-
ences. Nucleic Acids Res. 25(6), 1194–1202.
Rice, C. M. (1996). Flaviviridae: The viruses and their replication. In
“Fields Virology” (B. N. Fields, D. M. Knipe, P. M. Howley, R. M.
Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus,
Eds.), 3rd ed., pp. 931–959. Lippincott-Raven Publishers, Philadel-
phia.
Rosen, L., Drouet, M. T., and Deubel, V. (1999). Detection of dengue
virus RNA by reverse transcription-polymerase chain reaction in the
liver and lymphoid organs but not in the brain in fatal human infec-
tion. Am. J. Trop. Med. Hyg. 61(5), 720–724.
Shurtleff, A. C., Beasley, D. W., Chen, J. J., Ni, H., Suderman, M. T., Wang,
H., Xu, R., Wang, E., Weaver, S. C., Watts, D. M., Russell, K. L., and
Barrett, A. D. (2001). Genetic variation in the 3 non-coding region of
dengue viruses. Virology 281(1), 75–87.
Skiadopoulos, M. H., Surman, S. R., St Claire, M., Elkins, W. R., Collins,
P. L., and Murphy, B. R. (1999). Attenuation of the recombinant human
parainfluenza virus type 3 cp45 candidate vaccine virus is aug-
mented by importation of the respiratory syncytial virus cpts530 L
polymerase mutation. Virology 260(1), 125–135.
Takemoto, K. K. (1966). Plaque mutants of animal viruses. Prog. Med.
Virol. 8, 314–348.
138 BLANEY ET AL.
Thein, S., Aung, M. M., Shwe, T. N., Aye, M., Zaw, A., Aye, K., Aye, K. M.,
and Aaskov, J. (1997). Risk factors in dengue shock syndrome. Am. J.
Trop. Med. Hyg. 56(5), 566–572.
Troyer, J. M., Hanley, K. A., Whitehead, S. S., Strickman, D., Karron, R. A.,
Durbin, A. P., and Murphy, B. R. (2001). A live attenuated dengue-4
virus vaccine candidate with a 30 base pair deletion in its 3 un-
translated region has restricted capacity for dissemination in mos-
quitoes and is not transmitted from vaccinees to mosquitoes. Am. J.
Trop. Med. Hyg. 65(5), 414–419.
Vaughn, D. W., Hoke, C. H., Jr., Yoksan, S., LaChance, R., Innis, B. L.,
Rice, R. M., and Bhamarapravati, N. (1996). Testing of a dengue 2
live-attenuated vaccine (strain 16681 PDK 53) in ten American vol-
unteers. Vaccine 14(4), 329–336.
Wahid, S. F., Sanusi, S., Zawawi, M. M., and Ali, R. A. (2000). A com-
parison of the pattern of liver involvement in dengue hemorrhagic
fever with classic dengue fever. Southeast Asian J. Trop. Med. Public
Health 31(2), 259–263.
Whitehead, S. S., Firestone, C. Y., Collins, P. L., and Murphy, B. R. (1998).
A single nucleotide substitution in the transcription start signal of the
M2 gene of respiratory syncytial virus vaccine candidate cpts248/
404 is the major determinant of the temperature-sensitive and atten-
uation phenotypes. Virology 247(2), 232–239.
139SMALL-PLAQUE DENGUE VIRUS MUTANTS
